Xuanzhu Biopharmaceutical, an innovative drug research and development subsidiary of Hong Kong-listed Sihuan Pharmaceutical Holdings Group, has completed an 800-million-yuan ($116 million) Series A round of equity financing led by Chinese state-owned investment firm State Development and Investment Corporation (SDIC).
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in